Trevi Therapeutics (TRVI) Non Operating Income (2018 - 2025)

Trevi Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $1.9 million for Q4 2025.

• On a quarterly basis, Non Operating Income rose 123.7% year-over-year to $1.9 million in Q4 2025; TTM through Dec 2025 was $6.2 million, a 73.9% increase from a year earlier, with the FY2025 full-year figure at $6.5 million, up 81.55% from the prior year.
• Non Operating Income eased to $1.9 million in Q4 2025 per TRVI's latest filing, from $2.1 million in the prior quarter.
• Across five years, Non Operating Income topped out at $2.2 million in Q4 2022 and bottomed at -$297000.0 in Q1 2021.
• The 5-year median for Non Operating Income is $996000.0 (2024), against an average of $884105.3.
• Across the five-year window, Non Operating Income plunged 11900.0% in 2022 and surged 28775.0% in 2023, its largest moves.
• Year by year, Non Operating Income stood at $1.2 million in 2021, then surged by 73.35% to $2.2 million in 2022, then slumped by 47.52% to $1.1 million in 2023, then declined by 25.31% to $844000.0 in 2024, then jumped by 123.7% to $1.9 million in 2025.
• Per Business Quant, the three latest TRVI Non Operating Income figures stand at $1.9 million (Q4 2025), $2.1 million (Q3 2025), and $1.4 million (Q2 2025).